Durmuș Büșra, Yperzeele Laetitia, Zuurbier Susanna M
Department of Neurology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Antwerp, Belgium.
Department of Neurology, Stroke Unit & NeuroVascular Centre Antwerp, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Antwerp; Belgium.
Ther Adv Neurol Disord. 2020 Aug 3;13:1756286420945169. doi: 10.1177/1756286420945169. eCollection 2020.
Sex-specific risk factors for cerebral venous thrombosis (CVT) in women include oral contraceptives, pregnancy, puerperium, and hormone replacement therapy. The acute treatment of CVT is anticoagulation using therapeutic doses of low molecular weight heparin, which is also the preferred treatment in the post-acute phase in pregnancy and during breastfeeding. In patients with imminent brain herniation decompressive surgery is probably life-saving. A medical history of CVT alone is not a contraindication for future pregnancies. The optimal dosage of low molecular weight heparin as thrombosis prophylaxis during future pregnancies after a history of venous thrombosis including CVT is the topic of an ongoing trial.
女性脑静脉血栓形成（CVT）的性别特异性风险因素包括口服避孕药、妊娠、产褥期和激素替代疗法。CVT的急性治疗是使用治疗剂量的低分子量肝素进行抗凝，这也是妊娠后期和哺乳期急性后期的首选治疗方法。对于即将发生脑疝的患者，减压手术可能挽救生命。单纯CVT病史并非未来妊娠的禁忌证。对于有包括CVT在内的静脉血栓形成病史的女性，在未来妊娠期间预防血栓形成的低分子量肝素最佳剂量是一项正在进行的试验的主题。
